Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Study findings from Z.B. Mi et al broaden understanding of breast cancer
September 18th, 2008
"For chemosensitivity and resistance assays to be clinically useful in predicting patient outcome, they should require small amounts of tissue and be highly reproducible and reliable. Expanded tumor cells from transcutaneous biopsies of breast lesions (n = 62) were tested for chemoresponse using the cell-based ChemoFx(R) assay," researchers in the United States report. "Pathologic complete response (pCR) was determined on a subset of patients (n = 34). Assay score and pCR were determined independently in a blinded manner. Logistic regression models were used to select predictors for response. Tumor cells were successfully isolated from 83.9% of patients. Chemoresponse...
Source: Women's Health Weekly (2008-09-18)
|
